作者
Carolyn T Bramante, John B Buse, David M Liebovitz, Jacinda M Nicklas, Michael A Puskarich, Ken Cohen, Hrishikesh K Belani, Blake J Anderson, Jared D Huling, Christopher J Tignanelli, Jennifer L Thompson, Matthew Pullen, Esteban Lemus Wirtz, Lianne K Siegel, Jennifer L Proper, David J Odde, Nichole R Klatt, Nancy E Sherwood, Sarah M Lindberg, Amy B Karger, Kenneth B Beckman, Spencer M Erickson, Sarah L Fenno, Katrina M Hartman, Michael R Rose, Tanvi Mehta, Barkha Patel, Gwendolyn Griffiths, Neeta S Bhat, Thomas A Murray, David R Boulware, Blake Anderson, Riannon C Atwater, Nandini Avula, Kenny B Beckman, Jannis Brea, Courtney A Broedlow, Paula Campora, Anup Challa, Jill Charles, Grace Christensen, Theresa Christiansen, Bo Connelly, Srijani Datta, Nikita Deng, Alex T Dunn, Faith M Fairbairn, Daniel J Fraser, Regina D Fricton, Gwen Griffiths, Aubrey A Hagen, Audrey F Hendrickson, Nicholas E Ingraham, Arthur C Jeng, Darrell M Johnson, Erik A Kuehl, Derek D LaBar, Samuel Lee, Sarah Lindberg, Darlette G Luke, Rosario Machicado, Zeinab Mohamud, Rumbidzai Ngonyama, Elliott Parrens, Daniela Parra, Matthew F Pullen, Via Rao, Neha V Reddy, Naveen Reddy, Katelyn J Rypka, Hanna G Saveraid, Paula Seloadji, Arman Shahriar, Nancy Sherwood, Jamie L Siegart, Lucas Simmons, Isabella Sinelli, Palak Singh, Andrew Snyder, Maxwell T Stauffer, Jennifer Thompson, Tannon L Tople, Walker J Tordsen, Ray HB Watson, Beiqing Wu, Adnin Zaman, Madeline R Zolik, Lena Zinkl
发表日期
2023/10/1
期刊
The Lancet Infectious Diseases
卷号
23
期号
10
页码范围
1119-1129
出版商
Elsevier
简介
Background
Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SARS-CoV-2 infection could reduce the risk of long COVID.
Methods
We conducted a decentralised, randomised, quadruple-blind, parallel-group, phase 3 trial (COVID-OUT) at six sites in the USA. We included adults aged 30–85 years with overweight or obesity who had COVID-19 symptoms for fewer than 7 days and a documented SARS-CoV-2 positive PCR or antigen test within 3 days before enrolment. Participants were randomly assigned via 2 × 3 parallel factorial randomisation (1:1:1:1:1:1) to receive metformin plus ivermectin, metformin plus fluvoxamine, metformin plus placebo, ivermectin plus placebo, fluvoxamine plus placebo, or placebo plus placebo …
学术搜索中的文章
CT Bramante, JB Buse, DM Liebovitz, JM Nicklas… - The Lancet Infectious Diseases, 2023